Most cancers occur when there is an imbalance of cellular growth and inhibition, causing cells to grow rapidly and form tumors in the body. In the case of prostate cancer, no therapies exist to simultaneously correct tumor growth and restore tumor suppression. To restore this balance, researchers from Brigham and Women's Hospital, which is part of Harvard Medical School, have used lipid nanoparticles to deliver messenger RNA (mRNA) and small interfering RNA (siRNA) to human prostate cancer cells. This approach was successful in preclinical models, holding promise for suppressing tumor growth in patients.
An official website of the United States government.